Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Homocysteine as a predictor of cardiovascular adverse events in coronary artery disease
Session:
Painel 6- Doença Coronária 4
Speaker:
M. Raquel Santos
Congress:
CPC 2020
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
12. Coronary Artery Disease (Chronic)
Subtheme:
12.1 Coronary Artery Disease – Pathophysiology and Mechanisms
Session Type:
Posters
FP Number:
---
Authors:
M. Raquel Santos; Roberto Palma dos Reis; Andreia Pereira; Flávio Mendonça; Margarida Temtem; Adriano Sousa; Joel Monteiro; Ana Célia Sousa; Sónia Freitas; Eva Henriques; Ilídio Ornelas; A. Drumond de Freitas; Maria Isabel Mendonça
Abstract
<p><strong><u>Introduction:</u></strong></p> <p>After the diagnosis of coronary artery disease (CAD), traditional risk factors such as diabetes mellitus, dyslipidemia, hypertension and smoking have been used to assess the risk of major adverse cardiovascular events (MACE). However, despite reduction of these factors, presence of MACE remains high. It is necessary to identify other causal risk factors for MACE in coronary patients and increased plasma Homocysteine (Hcy) level seems to be a likely candidate. However, the influence of Hcy levels in the prognosis of coronary patients presents a limited knowledge.</p> <p><strong><u>Objective:</u></strong></p> <p>To evaluate the influence of high Hcy levels in MACE (defined as a composite endpoint of cardiovascular death, acute myocardial infarction, stroke, admission for heart failure and need to revascularization) of coronary artery patients from Madeira Island population.</p> <p><strong><u>Materials and Methods:</u></strong></p> <p>Study analyses of 1687 patients selected from GENEMACOR study population, with at least one > 75% coronary stenosis by angiography. Homocysteine was measured by fluorescence polarized immunoassay using an Abbot IMX automatic device. Population was divided in three terciles according to the Hcy levels and the population of the 2<sup>nd</sup> tercil (Hcy 11.1-13.6mmol/L) was excluded. The final population of 1118 patients had a median age of 53.1±7.9 years and 77.6% were men. We compared patients from the 1<sup>st</sup> (Hcy < 11.1mmol/L) and 3<sup>rd</sup> tercil (Hcy > 13.6mmol/L) during a mean follow up of 5.0±4.8 years.</p> <p><strong><u>Results:</u></strong></p> <p>560 (50.1%) patients were included in the 1<sup>st</sup> tercil group (median age 51.6±3 years, 72.0% men) and 558 (49.9%) patients were in the 3<sup>rd</sup> tercil group (median age 54.6±3 years, 83.3% men). In our population, high levels of Hcy were significantly associated with MACE (OR 1.43, 95% CI: 1.12-1.83, p 0.004).</p> <p><strong><u>Conclusion:</u></strong></p> <p>In our population, a higher level of Hcy was associated with adverse prognosis and increased occurrence of MACE, therefore it is essential, in these patients, to have a more intensive therapeutic strategy.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site